Expertos Invitados





BACTERIOTERAPIA CON LACTOBACILOS PROBIOTICOS PARA LA PREVENCION DE INFECCIONES UROGENITALES

(especial para SIIC © Derechos reservados)
La administración intrauretral de lactobacilos no produjo efectos adversos ni modificaciones estructurales o ultraestructurales en un modelo murino de investigación.
nadermacias9.jpg Autor:
María elena Nader-macias
Columnista Experto de SIIC

Institución:
Centro de Referencia para Lactobacilos (CERELA-CONICET)

Artículos publicados por María elena Nader-macias
Recepción del artículo
2 de Junio, 2005 		Aprobación
13 de Junio, 2005
Primera edición
6 de Febrero, 2006 		Segunda edición, ampliada y corregida
7 de Junio, 2021

BACTERIOTERAPIA CON LACTOBACILOS PROBIOTICOS PARA LA PREVENCION DE INFECCIONES UROGENITALES

Resumen
Los lactobacilos son los microorganismos predominantes en el tracto gastrointestinal y urogenital del hombre y los animales homeotermos. También se emplean en la elaboración de diferentes alimentos, lo que los categoriza como GRAS (generally regarded as safe). Si bien están disponibles en productos vaginales en el mercado farmacéutico, hay escasas evidencias de su efectividad para la prevención de infecciones urogenitales. Nuestro grupo de trabajo ha aislado lactobacilos vaginales humanos, seleccionando aquellos con propiedades benéficas o probióticas. Se han estudiado las características tecnológicas para obtener el mayor número de microorganismos vivos (biomasa) y las condiciones para la producción óptima de sustancias antagónicas frente a patógenos urogenitales (ácidos orgánicos, peróxido de hidrógeno, bacteriocinas). Se ha demostrado en animales de experimentación (ratones BALB/c hembra endocriados) que la administración intrauretral de lactobacilos no produce efectos adversos ni modificaciones estructurales o ultraestructurales, previniendo eficazmente las infecciones urinarias. Es necesaria la complementación de estos resultados con estudios en pacientes para demostrar la efectividad de la administración intravaginal de los lactobacilos probióticos seleccionados en la recolonización de la microbiota urogenital, la prevención o la terapia de los diferentes síndromes y cuadros clínicos que afectan al tracto, su efecto sobre las embarazadas, etc., que permitan proponer la bacterioterapia con lactobacilos como alternativa válida a la terapia con otras drogas.

Palabras clave
Lactobacilos, prevención, infecciones urogenitales, probióticos


Artículo completo
(castellano)
Extensión:  +/-4.75 páginas impresas en papel A4
Exclusivo para suscriptores/assinantes

BACTERIOTHERAPY WITH PROBIOTIC LACTOBACILLI FOR THE PREVENTION OF UROGENITAL INFECTIONS

Abstract
Lactobacilli are the predominant microorganisms in the gastrointestinal and urogenital tracts of human beings and homeotermic animals. They are also used for the elaboration of different fermented foods being categorized as GRAS (generally regarded as safe). Even though they are included into different vaginal products in the pharmaceutical market, there are small amount of evidences of their effectivity in the prevention of urogenital infections. Our research group have isolated human vaginal lactobacilli, selecting those with beneficial or probiotic properties. The technological characteristics to obtain the higher number of viable (biomass) microorganisms and the conditions for the optimal production of antagonistic substances against pathogenic microorganisms (organic acid, hydrogen peroxide, bacteriocins) were determined. In experimental animals (inbreed female BALB/c mice) we demonstrated that the intraurethral administration of lactobacilli does not produce adverse effects or structural or ultra structural modifications in the urogenital tract, preventing effectively the urinary tract infections. The complementation of these results with human assays is necessary to demonstrate effectively the intravaginal administration of selected probiotic lactobacilli on the recolonization of the urogenital microbiota, the prevention or therapy of different clinical syndromes, their effect on pregnant women, etc, that will allow the proposal of the bacteriotherapy with lactobacilli as a valid alternative to the other drugs therapies.

Key words
Lactobacilli, prevention, urinary tract infections, probiotic

Clasificación en siicsalud
Artículos originales > Expertos de Iberoamérica >
página   www.siicsalud.com/des/expertocompleto.php/

Especialidades
Principal: Infectología, Urología
Relacionadas: Bioquímica, Farmacología, Medicina Farmacéutica, Medicina Interna, Obstetricia y Ginecología



Comprar este artículo
Extensión: 4.75 páginas impresas en papel A4

file05.gif (1491 bytes) Artículos seleccionados para su compra




Patrocinio y reconocimiento:
Reconocimiento: Los resultados presentados en este trabajo han dado lugar a las tesis doctorales de los siguientes profesionales: Dra. Clara Silva de Ruiz, Dra. Virginia Ocaña y Dra. Silvina Juárez Tomas.
Los proyectos de investigación cuyos resultados se vuelcan en el presente trabajo han sido financiados por subsidios de CONICET.
Las cepas probióticas seleccionadas se licenciaron a la empresa italiana Anidral, del grupo Molfin-Ace-Probiotical, para su obtención en gran escala y comercialización mundial.
Bibliografía del artículo
  1. Reid G, Sanders ME, Gaskins R et al. New Scientific paradigms for probiotics and prebiotics. Journal of Clinical Gastroenterology 2003; 37:108-118.
  2. Cremonini F, Di Caro S, Nista EC et al. Metaanalysis: The effect of probiotic administration on antibiotic-associated diarrhea. Aliment Pharmacol Ther 2002; 16:1461-1467.
  3. Szajewska H, Mrukowics JZ. Probiotics in the treatment and prevention of acute infectious diarrea in infants and children: a systematic review of published randomized, double blind, placebo controlled trials. J Pedriatr Gastroentl Nutr 2001; 33(Supl2):S17-25.
  4. Sartor RB. Probiotic therapy of intestinal inflammation and infections. Curr Opin Gastroenterol 2005; 21:44-50.
  5. Weston S, Halbert AR, Richmond P, Prescott SL. Effect of probiotics on atopic dermatitis: a randomised controlled trial. Arch Dis Child 2005; 29.
  6. Gill HS, Guarner F. Probiotics and humal health: a clinical perspective. Postgrad Med J 2004; 80:516-526.
  7. Sullivan A, Nord CE. Probiotics and gastrointestinal diseases. J Intern Med 2005; 257:78-92.
  8. De Roos NM, Katan MB. Effects of probiotic bacteria on diarrea, lipid metabolism and carcinogenesis: a review of papers published between 1988 and 1998. Am J Clin Nutr 2000; 71:405-411.
  9. Savage DC, Kotarski SF. Models for study the specificity by which lactobacilli adhere to murine gastric epithelium. Inf and Immun 1979; 26:966-973.
  10. Ocaña VS, Bru E, De Ruiz Holgado AP, Nader-Macías ME. Surface characteristics of lactobacilli isolated from human vagina. J Gen Appl Microbiol 1999; 45:203-12.
  11. Ocaña VS, De Ruiz Holgado AP, Nader-Macías ME. Selection of vaginal H2O2-generating Lactobacillus for probiotic use. Current Microbiol 1999; 38:279-84.
  12. Ocaña VS, De Ruiz Holgado AP, Nader-Macías ME. Growth inhibition of Staphylococcus aureus by H2O2-producing Lactobacillus paracasei subsp. paracasei isolated from the human vagina. FEMS Immunol Med Microbiol 1999; 23:87-92.
  13. Ocaña VS, De Ruiz Holgado AP, Nader-Macías ME. Characterization of a bacteriocin-like substance produced by a vaginal Lactobacillus salivarius strain. Appl Env Microbiol 1999; 65:5631-35.
  14. Juárez Tomas MS, Ocaña VS, Wiesse B, Nader-Macías ME. Growth and Lactic acid production by vaginal Lactobacillus acidophilus CRL 1259, and inhibition of uropathogenic Escherichia coli. J Of Medical Microbiology 2003; 52:1117-1124.
  15. Hillier SL, Krhonh MA, Rabe LK, Klebanoff S, Eschenbach D. The normal vaginal flora, H202-producing lactobacilli and bacterial vaginosis in pregnant women, Clin Inf Diseases 1993; 16(S4):S273-281.
  16. Redondo-López V, Cook RL, Sobel JD. Emerging role of lactobacilli in the control and maintenance of the vaginal bacterial microflora. Rev Infect Dis 1990; 12:856-872.
  17. Esenbach Klebanoff SJ, Hillier SL, Eschenbach DA, Waltersdorph AM. Control of the microbial flora of the vagina by H2O2-generating lactobacilli. J Inf Dis 1991; 164:94-100.
  18. Nader Macías ME, López Bocanera ME, Silva Ruiz C, Pesce de Ruiz Holgado A. Isolation of lactobacilli from the urogenital tract of mice. Elaboration of beads for their inoculation. Microbiologie-Aliments-Nutrition 1992; 10:43-7.
  19. Silva Ruiz C, Nader-Macías ME, López Bocanera ME, Ruiz Holgado A. Lactobacillus fermentum administered in suspensions and in agarose beads to mice: a comparative study. Microbiologie Aliments Nutrition 1993; 11:391-397.
  20. Nader-Macías ME, Silva-Ruiz C, López-Bocanera ME, Pesce-Ruiz Holgado A. Behaviour of lactobacilli on prevention and therapeutic effects on urinary tract infections (UTI) in mice. Anaerobe 1996; 2:85-93.
  21. Silva de Ruiz C, Rey R, Nader-Macías ME. Structural and ultrastructural studies of the urinary tract of mice inoculated with Lactobacillus fermentum. British Journal of Urology 2003; 91:878-882.
  22. Silva Ruiz C, Lopez Bocanera ME, Nader Macias ME, Pesce de Ruiz Holgado A. Effect of lactobacilli and antibiotics on E. coli urinary tract infections in mice. Biol Pharmac Bull 1996; 19(1):88-93.
  23. Silva Ruiz C, Rey R, Nader Macías ME. Experimental administration of estradiol on the colonization of Lactobacillus fermentum and Escherichia coli in the urogenital tract of mice. Bio Pharm Bull 2001; 24:127-134.
  24. Vintini E; Ocaña V, Nader-Macias ME. Effect of lactobacilli administration in the vaginal tract of mice: evaluation of side effects and local immune response by local administration of selected strains. Methods Mol Biol 2004; 268:401-410.
  25. Juárez Tomás MS, Bru de Labanda E, de Ruiz Holgado AP, Nader-Macías ME. Estimation of vaginal probiotic lactobacilli growth parameters with the application of the Gompertz model. Can J Microbiol 2002; 48:82-92.
  26. Juárez Tomás MS, Ocaña V, Nader-Macías ME. Viability of vaginal probiotic lactobacilli during refrigerated and frozen storage. Anaerobe 2004; 10:1-5.
  27. Zárate G, Juárez Tomas MS, Nader-Macias ME. Effect of some pharmaceutical excipiente on the survival of probiotic vaginal lactobacilli. (2005) In press.
  28. Zárate G, Nader-Macias. Viability and biological properties of probiotic vaginal lactobacilli after lyophilization and refrigerated storage into gelatin capsules. (2005) In press.
  29. Juárez Tomás MS, Bru E, Nader-Macías ME. Comparison of the growth and hydrogen peroxide production by vaginal probiotic lactobacilli under different culture conditions. Am J Obstet Gynecol 2003; 188:35-44.
  30. Juárez Tomás MS, Bru E, Wiese B, de Ruiz Holgado AAP, Nader-Macías ME. Influence of pH, temperature and culture media on the growth and bacteriocin production of vaginal Lactobacillus salivarius CRL 1328. J Appl Microbiol 2002; 93 (4):714-724.
  31. Ocaña VS, Nader-Macias ME. Vaginal Lactobacilli: self and co-aggregating ability. British Journal of Biomedical Sciences 2002; 59:183-190.
  32. Juárez Tomás MS, Wiese B, Nader-Macias ME. Effects of culture conditions on the growth and auto-aggregation ability of vaginal Lactobacillus johnsonii CRL 1294. (2005) In press.
  33. Reid G, Bruce A, Taylor M. Influence of three days antimicrobial therapy and Lactobacilli vaginal suppositories on recurrence of urinary tract infections. Clin Therap 1992; 14:11-16.
  34. Baerheim S, Larsen E, Di Granes A. Vaginal application of lactobacilli in the prophylaxis of recurrent lower urinary tract infections in women. Scand J Prim Health Care 1994; 12:239-242.
  35. Raz R, Stamm W. A controlled trial of intravaginal estriol in postmenopausal women with recurrent urinary tract infections. New Eng J of Medicine 1993; 329:753-756.
  36. Parent J, Bossens M, Bayot D, et al. Therapy of bacterial vaginosis using exogenously applied lactobacillus acidophilus and a low dose of estriol. Drug Res 1996; 46:68-73.
  37. Mc Groarty J. Probiotic use of lactobacilli in the human female urogenital tract. FEMS Microb and Medical Microbiology 1993; 6:251-264.
  38. Reid G, Burton J. Use of Lactobacillus to prevent infection by pathogenic bacteria. Microbes and Infection 2002; 4:319-324.
  39. Boris S, Barbes C. Role played by lactobacilli in controlling the population of vaginal pathogens Microbes and Infection 2000; 2:543-546.
  40. Reid G, Bruce AW. Selection of Lactobacillus strains for urogenital probiotic applications. J Infect Dis 2001; 183(Suppl 1):S77-80.
  41. Reid G, Jass J, Sebulsky T, McCormick J. Potential uses of probiotics in clinical practice. Clin Microbiol Rev 2003; 16(4):658-72.
  42. Reid G, Beuerman D, Heinemann C, Bruce AW. Probiotic Lactobacillus dose required to restore and maintain a normal vaginal flora. FEMS Immunol Med Microbiol 2001; 32:37-41.
  43. Reid G, Bruce AW. Selection of lactobacillus strains for urogenital probiotic applications. J Infect Dis 2001; 183(suppl 1):S77-S80.
  44. Gardiner G, Heinemann C, Beuerman D, Bruce AW, Reid G. Persistence of Lactobacillus fermentum RC-14 and L. rhamnosus GR-1, but not L. rhamnosus GG in the human vagina as demonstrated by randomly amplified polymorphic DNA (RAPD). Clin Diagn Lab Immunol 2002; 9:92-96.
  45. Reid G, Cook RL, Bruce AW. Examination of strains of lactobacilli for properties which may influence bacterial interference in the urinary tract. J Urol 1987;138:330-335.
  46. Reid G. Probiotic agents to protect the urogenital tract against infection. Am J Clin Nutr 2001; 73(suppl):437S-443S.
  47. Reid G, Charbonneau D, Erb J, Kochanowski B, Beuerman D, Poehner R, Bruce AW. Oral use of Lactobacillus rhamnosus GR-1 and L. fermentum RC-14 significantly alters vaginal flora: randomized, placebo-controlled trial in 64 healthy women. FEMS Immunol Med Microbiol 2003; 35:131-134.
 
 
 
 
 
 
 
 
 
 
 
 
Está expresamente prohibida la redistribución y la redifusión de todo o parte de los contenidos de la Sociedad Iberoamericana de Información Científica (SIIC) S.A. sin previo y expreso consentimiento de SIIC.
ua31618

Copyright siicsalud © 1997-2024 ISSN siicsalud: 1667-9008